用于安全控制系统性红斑狼的疾病活动的三菌糖化物:一个系统性审查与元分析和试验顺序分析
Yifan Chen1, Liuding Wang1, Nannan Li1
1Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Frontiers in pharmacology
|August 21, 2023
概括
三糖化物片 (TGT) 可以安全地降低系统性红斑狼 (SLE) 患者的疾病活性. 这次元分析发现,TGT改善了狼活动和反应率,而不会增加不良事件,尽管需要更多的研究.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 三糖化物在治疗系统性红斑狼 (SLE) 方面有着悠久的历史,具有免疫调节性质.
- 在SLE患者中评估Tripterygium Glycosides Tablet (TGT) 的疗效和安全性对于临床实践至关重要.
研究的目的:
- 在被诊断为全身性红斑狼 (SLE) 的患者中,系统地评估Tripterygium Glycosides Tablet (TGT) 的益处和风险.
主要方法:
- 对8项随机对照试验 (RCT) 进行了元分析,涉及538名SLE患者.
- 评估了偏差风险,并使用试验序列分析 (TSA) 来验证聚合效应的可靠性.
- 分析了疾病活性,整体反应率 (ORR) 和不良事件的数据.
主要成果:
- 与传统治疗 (CTs) 相结合的TGT显著降低了狼活动 (MD = -1.66) 并改善了ORR (RR = 1.21) 与单独CTs相比.
- 减少狼活动的证据确定性低,而改善ORR的证据确定性中等.
- 在TGT加CTs和单独CTs之间没有观察到对不良反应总体发生率的显著差异.
结论:
- 三糖化物片 (TGT) 显示出在系统性红斑狼 (SLE) 患者中安全降低疾病活动的潜力.
- 目前的证据表明,TGT可能是SLE常规治疗的有益补充.
- 需要进一步进行高质量的研究,以确定TGT在SLE治疗中的临床疗效和长期安全性.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Diarrhea-Predominant IBS
212
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
212
Antiasthma Drugs: Leukotriene Modifiers
355
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
355
Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
150
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
150


